MONTREAL--(BUSINESS WIRE)--MyX Therapeutics Inc, a unique enabling mucosal delivery platform company, announces new data from preclinical studies confirming MyX’s mucosal targeting nanoparticle eye drop formulation allows once-a-week dosing. Dr Frank Gu, co-founder and Chief Scientific Officer (CSO), will present these data, today October 7, 2019 at the 9th annual Partnership Opportunities in Drug Delivery (PODD) conference, at 5:45 p.m. Eastern Time.
"MyX-001 data suggests a significant R&D achievement of our leading nanotechnology platform. The importance of this animal model data sets the stage for a conceivable and dreamy market disruptive reality of once or twice a week delivery for a non-invasive liquid drop to treat ocular diseases”, says Gregory White, co-founder and CEO of MyX Therapeutics.
“Long-duration ocular surface delivery of this platform can translate into a significant impact patient benefit and compliance for dry eye and other ocular diseases”, adds Dr Frank Gu, CSO.
MyX Thera business model is to create product development partnerships in both human and veterinary health sectors in order to improve efficacy and safety profile of existing drugs and/or maximize potential of innovative drugs under development through optimal mucosal delivery.
ABOUT MyX THERAPEUTICS INC
MyX Therapeutics (www.myxthera.com) is a unique enabling mucosal delivery platform technology company to focus on a product development licensing partnership business model. Its technology is a patented biodegradable delivery-adhesive nanoparticle which allows its team to create market sector differentiating novel products for various routes of administration, including ophthalmic, sublingual & intranasal, vaginal and gastrointestinal deliveries.
